Treatment Resistant Depression Market, by Drug Type (Antidepressants Atypical agents, others), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Depression is a mood disorder that causes a persistent feeling of sadness and a loss of interest. Also called major depressive disorder or clinical depression, it affects how patients feel, think, and behave and can lead to a variety of emotional and physical problems. Patients may have trouble doing normal day-to-day activities. Depression (major depressive disorder) is a common and serious medical illness that negatively affects how patients feel, the way they think, and how they act. Depression causes feelings of sadness and/or a loss of interest in activities patients once enjoyed. It can lead to a variety of emotional and physical problems. There are various drugs available for treatment of depression, such as antidepressants, which are medications that can help relieve symptoms of depression, social anxiety disorder, anxiety disorders, and seasonal affective disorder. The atypical agents, also known as second generation antipsychotics and serotonin-dopamine antagonists, are a group of antipsychotic drugs largely introduced to be used to treat psychiatric conditions.

Market Dynamics

Increasing inorganic activities such as fund raise by organizations in order to expand their presence in the global treatment resistant depression market is expected to drive the market growth over forecast period. For instance, in February 2022, Minded, the specialist in prescribing mental health medication online, announced US$ 25 million in seed funding. Investors included Streamlined Ventures, Link Ventures, The Tiger Fund, Unicorn Ventures, Trousdale Ventures, Gaingels, SALT Fund, TheFund, and the founders of Care.com, Bolt, Gravity Blanket, RXBAR, and Gilt.com, along with venture debt from Western Technology Investment (WTI).

Increasing development of novel therapeutics for the treatment of resistant depression by market players to launch their novel products is expected to drive market growth over forecast period. For instance, in September 2021, XWPharma Ltd., a biopharmaceutical company, announced dosing of subjects in its first-in-human study evaluating XW10508, the company's novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain.

Key features of the study:

• This report provides an in-depth analysis of the global treatment resistant depression market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global treatment resistant depression market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
• Key companies covered as a part of this study include AbbVie Inc., Lupin, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Bausch Health Companies Inc., Sanofi, Mallinckrodt, Johnson & Johnson, Merck & Co., Inc., Viatris Inc., Otsuka Holdings Co., Ltd., H. Lundbeck A/S, AstraZeneca, and Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global treatment resistant depression market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global treatment resistant depression market

Detailed Segmentation:

• Global Treatment Resistant Depression Market, by Drug Type :
  • Antidepressants
    • Selective Serotonin Reuptake Inhibitors
    • Serotonin-norepinephrine Reuptake Inhibitors
    • Others
  • Atypical agents
  • Others
• Global Treatment Resistant Depression Market, by Distribution Channel :
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Treatment Resistant Depression Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Lupin
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • Sanofi
  • Mallinckrodt
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Viatris Inc.
  • Otsuka Holdings Co., Ltd.
  • Lundbeck A/S
  • AstraZeneca
  • Aurobindo Pharma Ltd.

"*" marked represents similar segmentation in other categories in the respective section.